Trial Profile
Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-Alpha vs. Imatinib/Low-Dose AraC vs. Interferon-Alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Cytarabine; Hydroxycarbamide; Interferon alpha
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms CML Study IV
- 06 Jun 2017 Ten-year overall survival results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
- 10 Dec 2012 Status changed from recruiting to active, no longer recruiting according to abstract presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.